Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms

Psychopharmacology

Volumn 230, Issue 1, 2013, Pages 49-55

  Cai, Jun ^a   Zhang, Wen ^b   Yi, Zhenghui ^a   Lu, Weihong ^a   Wu, Zhiguo ^a   Chen, Jun ^a   Yu, Shunying ^a   Fang, Yiru ^a   Zhang, Chen ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

Clozapine; Gene gene interaction; Glutamate transmission; Obsessive compulsive symptom; Schizophrenia

Indexed keywords

ADENINE; CLOZAPINE; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMATE RECEPTOR; GUANINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEIN GRIK2; THYMINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GRIK2 GENE; GRIN2B GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SLC1A1 GENE; SYMPTOM; TREND STUDY; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSS-SECTIONAL STUDIES; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84886285680     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3137-2     Document Type: Article

References (38)

1. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA (2004) Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 174:530-538
2. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006) Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63:769-776
3. Arnold PD, Macmaster FP, Hanna GL, Richter MA, Sicard T, Burroughs E, Mirza Y, Easter PC, Rose M, Kennedy JL, Rosenberg DR (2009) Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder. Brain Imaging Behav 3:64-76
4. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006633
5. Atmaca M, Yildirim H, Ozdemir H, Aydin A, Tezcan E, Ozler S (2006) Volumetric MRI assessment of brain regions in patients with refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:1051-1057
6. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-1740
7. Conne B, Stutz A, Vassalli JD (2000) The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 6:637-641
8. de Haan L, Linszen DH, Gorsira R (1999) Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 60:364-365
9. Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, Maier W, Bourgeron T, Leboyer M (2004) Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport 15:699-702
10. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL (2006) Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63:778-785
11. Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM (2005) Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 59:219-222
12. Evins AE, Amico ET, Shih V, Goff DC (1997) Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 104:761-766
13. Fenton WS, McGlashan TH (1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143:437-441
14. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011
15. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19:376-382
16. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108
17. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, Leboyer M, Bourgeron T (2002) Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 7:302-310
18. Kayahan B, Ozturk O, Veznedaroglu B, Eraslan D (2005) Obsessive-compulsive symptoms in schizophrenia: prevalence and clinical correlates. Psychiatry Clin Neurosci 59:291-295
19. Khullar A, Chue P, Tibbo P (2001) Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 26:55-59
20. Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, Choi JS, Kim B, Kang DH, Oh S, Park T, Hong KS (2009) Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 66:1233-1241
21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
22. Liu BC, Zhang J, Wang L, Li XW, Wang Y, Ji J, Yang FP, Wan CL, Gao LH, Xu YF, Feng GY, He L, Zhao XZ, He G (2010) No association between EGR gene family polymorphisms and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 34:506-509
23. Marazziti D, Carlini M, Dell'Osso L (2012) Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia. Curr Top Med Chem 12:238-253
24. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610
25. Ongur D, Goff DC (2005) Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 75:349-362
26. Pauls DL (2008) The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C Semin Med Genet 148C:133-139
27. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096-1103
28. Ryu S, Oh S, Cho EY, Nam HJ, Yoo JH, Park T, Joo YH, Kwon JS, Hong KS (2011) Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am J Med Genet B Neuropsychiatr Genet 156B:949-959
29. Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H (2009) Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry 50:437-442
30. Sampaio AS, Fagerness J, Crane J, Leboyer M, Delorme R, Pauls DL, Stewart SE (2011) Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci Ther 17:141-147
31. Samuels J, Wang Y, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Knowles JA, Piacentini J, Cullen B, Bienvenu OJ 3rd, Rasmussen SA, Geller D, Pauls DL, Liang KY, Shugart YY, Nestadt G (2011) Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 156B:472-477
32. Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10:88-95
33. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 41:2361-2373
34. Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97-98
35. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, Jenike E, Chabane N, Leboyer M, Delorme R, Jenike MA, Pauls DL (2007) Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 144B:1027-1033
36. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI (2005) Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet 8:450-458
37. Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012) The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 100:726-735
38. Zhang C, Li Z, Shao Y, Xie B, Du Y, Fang Y, Yu S (2011) Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci 43:406-411